Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithira Vasu

Showing results (31-40 of 102) with videos related to

Pageof 11
Sort By:
Blood Advances|June 3, 2026
TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium studyTheresa Hahn, Qiuhong Zhao, Elizabeth Greer Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2022
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Kendra L Sweet, Anthony S Stein, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 14, 2020
The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating AgentMichael Ozga, Ying Huang, James S Blachly, et al.
Blood|February 27, 2015
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, et al.
Leukemia & Lymphoma|February 16, 2019
Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experienceFiliz Yucebay, Christina Matthews, Marcin Puto, et al.
Haematologica|January 15, 2026
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness levelNaveen Pemmaraju, Marco Herling, Kendra L Sweet, et al.
Leukemia & Lymphoma|November 24, 2020
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDSBrendan Rasor, Tyler Dickerson, Qiuhong Zhao, et al.
Leukemia & Lymphoma|June 12, 2024
Impact of chronic graft-<i>versus</i>-host disease on non-relapse mortality and survivalJustin Jiang, Audrey M Sigmund, Qiuhong Zhao, et al.
Blood Advances|April 29, 2022
Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapyMax Yano, Chia Sharpe, J Rachel Lance, et al.
Leukemia & Lymphoma|July 4, 2015
Tocilizumab for steroid refractory acute graft-versus-host diseaseJulianna V F Roddy, Bradley M Haverkos, Ali McBride, et al.
Pageof 11

Showing results (31-40 of 102) with videos related to

Sort By:
Pageof 11
Blood Advances|June 3, 2026
TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium studyTheresa Hahn, Qiuhong Zhao, Elizabeth Greer Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2022
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Kendra L Sweet, Anthony S Stein, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 14, 2020
The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating AgentMichael Ozga, Ying Huang, James S Blachly, et al.
Blood|February 27, 2015
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, et al.
Leukemia & Lymphoma|February 16, 2019
Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experienceFiliz Yucebay, Christina Matthews, Marcin Puto, et al.
Haematologica|January 15, 2026
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness levelNaveen Pemmaraju, Marco Herling, Kendra L Sweet, et al.
Leukemia & Lymphoma|November 24, 2020
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDSBrendan Rasor, Tyler Dickerson, Qiuhong Zhao, et al.
Leukemia & Lymphoma|June 12, 2024
Impact of chronic graft-<i>versus</i>-host disease on non-relapse mortality and survivalJustin Jiang, Audrey M Sigmund, Qiuhong Zhao, et al.
Blood Advances|April 29, 2022
Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapyMax Yano, Chia Sharpe, J Rachel Lance, et al.
Leukemia & Lymphoma|July 4, 2015
Tocilizumab for steroid refractory acute graft-versus-host diseaseJulianna V F Roddy, Bradley M Haverkos, Ali McBride, et al.
Pageof 11